Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 5, 2008, Pages 333-340

  Batlle, Javier ^a,c   Villar, Ana ^a   Liras, Antonio ^a   Alonso, Concepción ^a   Altisent, Carmen ^a   Brito, Dilia ^a   Moreno, Manuel ^a   Lucía, Félix ^a   Sedano, Carmen ^a   Prieto, Manuel ^a   Calvente, Natividad ^a   Aznar, José A ^a   Jiménez, Víctor ^a   Soriano, Vicente ^a   Martorell, Javier R ^a   Iruín, Gemma ^a   Bergua, Juan M ^a   Aguilar, Carlos ^b  

^a Royal Foundation Victoria Eugenia   (Spain)

^b HOSPITAL SANTA BÁRBARA   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Emerging pathogens; Haemophilia; Plasma; Recombinant therapy; Safety

Indexed keywords

ANTIRETROVIRUS AGENT; BLOOD CLOTTING FACTOR 7A INHIBITOR; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; HEMOSTATIC AGENT; PLASMA DERIVED FACTOR VIII; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLEEDING DISORDER; BLOOD; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD TRANSFUSION; CANADA; CLINICAL TRIAL; COHORT ANALYSIS; CONSENSUS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EUROPE; EVIDENCE BASED PRACTICE; HEALTH CARE MANAGEMENT; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORGANIZATION AND MANAGEMENT; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SPAIN; TREATMENT INDICATION; UNCERTAINTY; UNITED STATES;

BLOOD COMPONENT TRANSFUSION; BLOOD-BORNE PATHOGENS; HEMOPHILIA A; HEPATITIS C; HIV; HIV INFECTIONS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF HEALTH CARE; QUALITY OF LIFE; SPAIN; VIRUS INACTIVATION;

EID: 62149140592     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328300c814     Document Type: Review

References (50)

1. Stanley S. The need for continuing vigilance: addressing the threat for transmission of blood-borne infectious disease. Semin Hematol 2006; 43 (Suppl 3):S17-S22.
2. Pipe S. Consideration in hemophilia therapy selection. Semin Hematol 2006; 43 (Suppl 3):S1-S3.
3. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA 2003; 289:959-962.
4. Dodd RY. Emerging infections, transfusion safety, and epidemiology. N Engl J Med 2003; 349:1205-1206.
5. Farruggia A. Safety and supply of haemophilia products: worldwide perspectives. Haemophilia 2004; 10:327-333.
6. Ironside JW. Variant Creutzfeldt-Jakob disease: risk of transmission by blood transfusion and blood therapies. Haemophilia 2006; 12 (Suppl 1): 8-15.
7. Ironside JW, Head MW. Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products. Haemophilia 2004; 10:64- 69.
8. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363:417-421.
9. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364:527-529.
10. Fourth case of transfusion-associated variant-CJD infection. http:// www.hpa.org.uk/hpr/archives/2007/news2007/news0307.htm.
11. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine epidemiological review study. Vox Sang 2006; 91:221-230.
12. Foster PR, Welch AG, McLean C, Griffin BD, Hardy JC, Bartley A, et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 2000; 78:86- 95.
13. Saa P, Castilla J, Soto C. Presymptomatic detection of prions in blood. Science 2006; 313:92-94.
14. Centers for Disease Control and Prevention. CDC's Universal Data Collection project: blood safety. 2006; Published online at http:// www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4271b1-index.htm.
15. Evatt B. Infectious disease in the blood supply and the public health response. Semin Hematol 2006; 43 (Suppl 3):S4-S9.
16. Pipe S. The physician's role in selecting a factor replacement therapy. Haemophilia 2006; 12 (Suppl 1):21-25.
17. Stoto M. The precautionary principle and emerging biologic risks: lessons from human immunodeficiency virus in blood products. Semin Hematol 2006; 43 (Suppl 3):S10-S12.
18. Dolan G. Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience. Haemophilia 2006; 12 (Suppl 1):16-20.
19. Ludlam CA, Powderly WG, Bozzette S, Diamond M, Koerper MA, Kulkarni R, et al. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet 2006; 367:252-261.
20. Farrugia A. Evolving perspectives in product safety for haemophilia. Haemophilia 2002; 8:236-243.
21. Aledort LM. Making a therapeutic choice: human versus recombinant fractions - can we do it? Haemophilia 2001; 7 (Suppl 1):1-3.
22. Mannucci PM. The choice of plasma-derived clotting factor concentrates. Baillieres Clin Haematol 1996; 9:273-290.
23. Mantovani LG, Monzini MS, Mannucci PM, Scalone L, Villa M, Gringeri A. Differences between patients, physicians and pharmacists preferences for treatment products in haemophilia: a discrete choice experiment. Haemophilia 2005; 11:589-597.
24. Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107:46-51.
25. Chalmers EA, Brown SA, Keeling D, Liesner R, Richards M, Stirling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13:149-155.
26. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109:4693-4697.
27. DiMichele D. Immune tolerance therapy for factor VIII inhibitors: moving from empiricism toanevidence-based approach. JThromb Haemost 2007; 5 (Suppl 1):143-150.
28. Public statement. Review of recombinant Factor VIII products and inhibitor development. EMEA/310225/2007Corr. http://www.emea.europa.eu/ pdfs/human/press/pus/31022507en.pdf.
29. Poon M-C, Lillicrap D, Hensman C, Card R,Scully M-F. Recombinant factor IX recovery and inhibitor safety: a Canadian postlicensure surveillance study. Thromb Haemost 2002; 87:431-435.
30. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL, Recombinant Factor IX Study Group. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98:3600-3606.
31. Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19:139-148.
32. Association of Hemophilia Clinic Directors of Canada. Clinical practice guidelines: hemophilia and von Willebrand's disease: 2. Management (Edition 2, Update 2). 7 July 1999. Published online at http:// www.ahcdc.ca/vWDManagement. html. [Accessed April 2005].
33. United Kingdom Haemophilia Centre Doctors- Organisation on behalf of The Department of Health Forward Planning and Monitoring Group. Rollout of recombinant products for all adult haemophilia patients in England: Report of 2003/2004. 2004. Published online at http://www.dh.gov.uk/ assetRoot/04/09/00/ 63/04090063.pdf.
34. United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO). Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003; 9:1-23.
35. Giangrande P, Haemophilia B. Christmas disease. Expert Opin Pharmacother 2005; 6:1517-1524.
36. Chambost H, LjungR. Changing pattern of care of boys with haemophilia in western European centres. Haemophilia 2005; 11:92-99.
37. Mauser-Bunschoten EP, Roosendaal G, van den Berg HM. Product choice and haemophilia treatment in the Netherlands. Haemophilia 2001; 1:96- 98.
38. Stonebraker JS, Amand RE, Bauman MV, Nagle AJ, Larson PJ. Modelling haemophilia epidemiology and treatment modalities to estimate the unconstrained factor VIII demand. Haemophilia 2004; 10:18-26.
39. Stonebraker JS, Amand RE, Nagle AJ. A country-by-country comparison of FVIII concentrate consumption and economic capacity for the global haemophilia community. Haemophilia 2003; 9:245-250.
40. Haya S, López MF, Aznar JA, Batlle J, Spanish Immune Tolerance Group. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia 2001; 7:154-159.
41. Martínez MM, Ortega F, Pinilla J. AIDS and hemophilia: experience in the La Paz Hemophilia Center. Haemostasis 1992; 22:281-292.
42. Quintana M, del Amo J, Barrasa A, Pérez-Hoyos S, Ferreros I, Hernández F, et al. Progression of HIV infection and mortality by hepatitis C infection in patients with haemophilia over 20 years. Haemophilia 2003; 9:605-612.
43. Aguilar C, Lucía JF. Hepatitis C and hemophilia. Med Clin (Barc) 1995; 105:139-141.
44. Ministry of Health. HIV/AIDS epidemiological surveillance in Spain. National register of AIDS cases. Update to June 2007. http://www.isciii.es/ htdocs/centros/epidemiologia/epi-sida.jsp.
45. Plug I, Van Der Bom JG, Peters M, Mauser-Bunschoten EP, De Goede-Bolder A, Heijnen L, et al. Mortality and causes of death in patients with hemophilia, 1999-2001: a prospective cohort study. J Thromb Haemost 2006; 4:510-516.
46. Arrieta R, Aznar JA, Magallón M, Padilla A, Serrano MA, Tusell J, et al. Therapy with plasma derived concentrates in haemophilia A. Sangre 1994; 39:157-162.
47. Arrieta R, Aznar JA, Magallón M, Padilla A, Serrano MA, Tusell et al. Guidelines on the choice of plasma derived prothrombin and factor IX concentrates in haemophilia B. Sangre 1994; 39:315-322.
48. Alonso C, Arrieta R, Aznar JA, Gómez JL, Magallón M, Medarde A, et al. Guidelines on the choice of factor VIII and IX concentrates. Sangre 1997; 42:437-444.
49. Alonso C, Aznar JA, Batlle J, Magallón M, Moreno M, Serrano MA, et al. Guidelines on the choice of concentrates in haemophilia therapy. Sangre 1998; 43:451-452.
50. Farrugia A, Robert P. Plasma protein therapies: current and future perspectives. Best Pract Res Clin Haematol 2006; 19:243-258.